Of note, although ARPIs could prolong the progression-free survival of PCa patients, the PSA response rate associated with ARPIs is below 80%, with about 20% of patients exhibiting no response to ARPIs13. The gene discussed is KLK3; the disease is posterior cortical atrophy.